From GlobeNewswire: 2025-02-24 07:00:00

BioCryst Pharmaceuticals reported strong financial results for Q4 2024, with ORLADEYO net revenue up 36.6% y-o-y to $124.2 million and FY 2024 net revenue at $437.7 million, up 34.3% y-o-y. The company increased its FY 2025 ORLADEYO revenue guidance to $535-$550 million and expects to achieve positive EPS and cash flow in 2H 2025.

BioCryst anticipates expanding the ORLADEYO label to children aged 2 to 11 with HAE using an oral granule formulation. Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema are expected by the end of the year. The company plans to submit an NDA this year.

For Q4 2024, BioCryst reported total revenues of $131.5 million, up 40.8% y-o-y, with ORLADEYO net revenue at $124.2 million. Non-GAAP operating profit was $16.8 million. The company’s GAAP operating loss was $4.5 million for Q4 2024, compared to $42.7 million in Q4 2023.

In FY 2024, BioCryst’s total revenues reached $450.7 million, with ORLADEYO net revenue at $437.7 million. Non-GAAP operating profit was $62.9 million. The company expects its global net ORLADEYO revenue for FY 2025 to be between $535 million and $550 million, with total revenue between $560 million and $575 million. Positive EPS and cash flow are expected in 2H 2025.



Read more at GlobeNewswire:: BioCryst Reports Fourth Quarter and Full Year 2024